Therapeutic restoration of miR‐19a‐3p or blockade of TGF‐β reinforced the CD4+ T cell anti‐tumour activity and restrained the progression of HBx‐overexpressing DLBCL in vivo. This evidence concerns the gene TGFB1 and diffuse large B-cell lymphoma.